Aveva Drug Delivery Systems Introduces Innovative Fentanyl Patch
Aveva Drug Delivery Systems Launches Generic Fentanyl Patch
Aveva Drug Delivery Systems, part of DifGen, is pleased to announce the launch of all strengths of its generic Fentanyl Transdermal Patch in the US market. This innovative transdermal system serves as a prescription solution for managing moderate to severe chronic pain, providing a generic equivalent to Duragesic.
Enhancing Chronic Pain Management
The Fentanyl Transdermal System (TDS) is designed for extended release, ensuring around-the-clock pain relief for patients who require long-term opioid therapy. The development of this patch involved the rapid sourcing and seamless integration of advanced manufacturing equipment to meet stringent regulatory and operational standards.
Market Impact and Sales Potential
This product is notable, especially with reported US sales around USD 182 million. The patches are manufactured to meet strict safety, efficacy, and compliance standards, addressing the growing need for efficient pain management solutions in the healthcare sector.
Commitment to Patient Care
Ramandeep Singh Jaj, Founder and Co-CEO of DifGen Pharmaceuticals, emphasized the importance of this launch, stating that chronic pain can heavily impact an individual's quality of life. Jaj mentioned the necessity of providing patients and healthcare providers with reliable options that mitigate consistent supply interruptions, which often lead to shortages in the healthcare system.
Addressing Challenges in Opioid Use
Dr. Santhanakrishnan Srinivasan, another Founder and Co-CEO within the company, highlighted that the Fentanyl TDS employs matrix-based technology aimed at deterring potential abuse. This patch is available in eight strengths, ranging from 12.5mcg to 100mcg, allowing for personalized pain management tailored to each patient's needs.
Technological Advancements in Manufacturing
Aveva’s manufacturing process utilizes an adhesive technology designed not only for comfort but also for durability. The patches incorporate a tamper-evident design to promote responsible opioid usage, an essential factor in today’s healthcare landscape.
About DifGen Pharmaceuticals
DifGen is a globally operating pharmaceutical company that emphasizes creating complex generic and specialty pharmaceutical products. The company is dedicated to enhancing the accessibility of quality medications, ultimately striving to establish healthier communities.
Aveva Drug Delivery Systems
Aveva Drug Delivery Systems, a subsidiary of DifGen, is a fully integrated developer and manufacturer of sterile pharmaceutical products, focusing on Transdermal Delivery Systems and Oral Dissolvable Films. Situated in Florida, Aveva is DEA approved for the storage and handling of controlled substances and demonstrates impressive manufacturing capabilities.
Manufacturing Strengths
Aveva's extensive facilities span 210,000 square feet and have a current production capacity of approximately 500 million patches per year. Their FDA-registered manufacturing site is equipped with state-of-the-art technology that efficiently handles various dosage forms, ensuring product reliability and safety.
Contact Information
For further inquiries, Dr. Srinivasan Vedantham can be contacted at 954-430-3340. Aveva focuses on building a comprehensive solution for providing medications that meet consumer needs while ensuring safety and effective pain management.
Frequently Asked Questions
What is the purpose of the Fentanyl Transdermal Patch?
The Fentanyl Transdermal Patch is designed to manage moderate to severe chronic pain through continuous delivery of the medication over a three-day period.
How does the patch help prevent opioid abuse?
The patch utilizes matrix-based technology and a tamper-evident design to reduce the risk of misuse and promote responsible medication usage.
What variations does the Fentanyl Patch come in?
The Fentanyl patch is available in eight different strengths, ranging from 12.5mcg to 100mcg, allowing for customized pain management solutions.
Who is responsible for the development of this patch?
Aveva Drug Delivery Systems, a part of DifGen Pharmaceuticals, specializes in creating advanced transdermal systems and is responsible for bringing this product to market.
What other products does Aveva provide?
Aveva develops a variety of pharmaceutical products, including sterile solutions, transdermal delivery systems, and oral dissolvable films, contributing to a broader range of healthcare solutions.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.